InvestSMART

Vectus Biosystems Limited (ASX:VBS)

ALERT: Price-sensitive ASX Announcement for VBS
Current share price for VBS : $0.160 0.01 (6.67%)+
Announcement
Release
14 Apr 2026 8:12AM
Price at Release
$0.150
Full Release
download
Summary
Vectus Biosystems Limited announced the settlement of its transaction involving the VB4-P5 Renal Compound with XORTX Therapeutics Inc. on April 14, 2026. This agreement, initially signed on October 17, 2025, involved Vectus transferring patents and intellectual property related to VB4-P5 to XORTX in exchange for 154,544 common shares and 692,150 pre-funded warrants, representing a 9.9% shareholding in XORTX. The transaction aligns with Vectus' strategy to develop drug candidates to a stage where they attract pharmaceutical partners, while maintaining a non-financial interest in the compound's further development. Vectus continues to pursue the commercialisation of its other compounds, notably VB0004, with no anticipated financial obligations for the VB4-P5 development.
Key Points
  • Vectus signed a binding Term Sheet with XORTX Therapeutics for VB4-P5 Renal Compound.
  • Vectus received 154,544 common shares and 692,150 pre-funded warrants from XORTX.
  • Vectus maintains a shareholding in XORTX and interests in VB4-P5's development.
  • No financial contribution is required from Vectus for further development of VB4-P5.
  • Vectus entered a voluntary lock-up agreement for XORTX securities.
  • Vectus is focused on commercialising its lead compound VB0004 and other emerging leads.
  • XORTX develops medications targeting purine metabolism and xanthine oxidase.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.